Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

NINDS Request for Information on Advancing Research in Parkinson’s Disease 2014


Notice Number: NOT-NS-13-035

Key Dates: Release Date: July 11, 2013

Related Notices: None

Issued by: National Institute of Neurological Disorders and Stroke (NINDS)

Responses requested by September 30, 2013

The National Institute of Neurological Disorders and Stroke (NINDS) is the primary federal agency responsible for funding research on Parkinson's Disease (PD).  On January 6-7, 2014, the NINDS will sponsor a public conference to assess critical needs and related opportunities for advancing PD research and treatment.

The purpose of this time-sensitive Request for Information (RFI) is to seek comprehensive perspective on the most significant challenges and highest priorities for basic, translational and clinical research on PD.

This RFI is intended to gather information relevant to conference planning and should not be construed as a funding opportunity.

Information Requested

This RFI is intended to solicit broad community perspective on scientific opportunities and outstanding needs for research and treatment of Parkinson's Disease (PD).

The NINDS invites input from stakeholders including but not limited to researchers in academia and industry, healthcare professionals, patient advocates and advocacy organizations, scientific and professional organizations, Federal agencies and other interested members of the public. Organizations are encouraged to submit a single response that reflects the views of the organization as a whole. Responses will be used to inform the 2014 NINDS PD conference.

The NINDS is interested in basic, translational and clinical PD research, as well as interdisciplinary approaches that span these areas. Please provide perspectives on the following questions:

Basic Research

1. What is currently the highest priority issue in laboratory-based research that must be answered in order to transform PD research and treatment, and why?




  1. If this basic research priority was accomplished, what would be the effect on one or more of the following: laboratory-based science, clinical trials, patient well-being, and public health?



  2. What specific elements are required to address this basic research priority and to remove any related obstacles? Examples of such elements might include: enhanced tools, technologies, other research resources; novel combinations of research team expertise and collaboration; bioinformatics resources; infrastructure. Please be specific.


Translational Research

2. What is currently the highest priority for moving research discoveries to treatments (or diagnostics) that will decrease the burden of illness due to PD, and why?


  1. If this translational research priority was accomplished, what would be the effect on one or more of the following: laboratory-based science, diagnosis, therapeutic trials, patient well-being and public health?


  2. What specific elements are required to address this translational research priority and to remove any related obstacles? Examples of such elements might include: enhanced tools, technologies, other research resources; novel combinations of research team expertise and collaboration; bioinformatics resources; infrastructure. Please be specific.


Clinical Research

3. What is currently the highest priority to be pursued through clinical research to reduce the burden of illness due to PD, and why?


  1. If this clinical research priority was accomplished, what would be the effect on one or more of the following: laboratory-based science, clinical trials, patient well-being, and public health?


  2. What specific elements are required to address this clinical research priority and to remove any related obstacles? Examples of such elements might include: enhanced tools, technologies, other research resources; novel combinations of research team expertise and collaboration; bioinformatics resources; infrastructure. Please be specific.


Additional Questions

4. What are the most important challenges (new and/or ongoing) for PD research and treatment?



5. What are other important current opportunities for advancing PD research and treatment?


6. Are there other topics that should be considered at an upcoming 2014 PD conference (see NOT-NS-13-035)?



General Information

Note: all of the following fields are optional. Proprietary, classified, confidential, or sensitive information should not be included in your response.

1. Please identify the nature of your interest in Parkinson’s Disease Research (i.e. are you a biomedical or clinical researcher, a member of an advocacy or community group, an interested member of the public, or other?).


2. If you are an investigator, please indicate your career level and main area of research interest, including focus on basic, translational and/or clinical research, as well as your general institutional affiliation (e.g. academic, industry, government, or other).


3. If you are a member of a particular advocacy or professional organization, please indicate the name and primary focus of the organization (i.e. research support, patient care, etc.) and whether you are responding on behalf of your organization (if not, please indicate your position within the organization).


4. Please provide your name and e-mail address (Optional):

:  

:  

Responses:

To ensure consideration, your responses must be received by September 30, 2013. Responses to this RFI must be submitted electronically using the web-based format at www.ninds.nih.gov/funding/RFI-PD.htm

Responses to this RFI are voluntary. Please do not include any personally identifiable or other information that you do not wish to make public. Proprietary, classified, confidential or sensitive information should not be included in your response. Comments submitted will be compiled for discussion at the upcoming January 2014 conference and may appear in related reports. Any personal identifiers (names, e-mail addresses, etc.) will be removed when responses are compiled.

This RFI is for informational and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the United States (US) Government, the NIH or the NINDS to provide support for any ideas submitted in response to it. Please note that the US Government, the NIH and the NINDS will not pay for the preparation of any information submitted, or for its use of that information.

Inquiries:

Please direct specific questions about this RFI to:

Beth-Anne Sieber, PhD
Program Director, Neurodegeneration
National Institute of Neurological Disorders and Stroke
National Institutes of Health
sieberb@ninds.nih.gov

Last updated July 31, 2013